

Christine Kleber <christine.kleber@vetter-pharma.com> 09.05.2009 12:13	To	juergen.sigg@novartis.com
	Cc	[REDACTED]@vetter-pharma.com>, christophe.royer@novartis.com, K: [REDACTED]@vetter-pharma.com>, [REDACTED]@vetter-pharma.com>
	Subject	Action item

Hi Juergen,
I'm not sure, what you did expect regarding the following action item.

7	▼	Siliconization Study	First overview of rational regarding established levels of silicone at Vetter	[REDACTED]	15-May-2009	Open
---	---	----------------------	---	------------	-------------	------

Is the explanation given in the development plan sufficient and can we close this action item?
More details regarding our siliconisation process could follow till end of May.

Kind regards,
[REDACTED]

Vetter Pharma-Fertigung GmbH & Co. KG

[REDACTED]
Process Development & Implementation
Schützenstrasse 87
88212 Ravensburg

Phone: +49-751-37 00 -2384
Fax.: +49-751-37 00 - 4002
E-Mail: [REDACTED]@vetter-pharma.com
Internet: www.vetter-pharma.com